ORPHA:85321
Deafness-intellectual disability syndrome, Martin-Probst type
Also known as: Hearing loss-intellectual disability syndrome, Martin-Probst type · Martin-Probst syndrome · X-linked deafness-intellectual disability syndrome · X-linked hearing loss-intellectual disability syndrome
Publications
11
19.9th percentile
Trials
0
Interventional, condition-specific
Researchers
62
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare X-linked syndromic characterized by sensorineural hearing loss, varying degrees of , short stature, and facial features (such as telecanthus, epicanthic folds, broad nasal root, malar hypoplasia, low-set ears, dental anomalies, and micrognathia). Additional reported manifestations include microcephaly, renal and genitourinary abnormalities, widely spaced, hypoplastic nipples, and adult onset of pancytopenia.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010353
- MeSH:C564495
- OMIM:300519
- UMLS:C1845285
Additional Mondo synonyms (4)
X-linked deafness-intellectual disability syndrome syndrome · intellectual disability, X-linked, syndromic, Martin-Probst type · martin-probst syndrome, X-linked recessive · mental retardation, X-linked, syndromic, Martin-Probst type
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
11 matched papers (5 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
11
11 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
11 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
5 in the last 10 years · high confidence · 19.9th percentile (publications denominator)
Phrase hits: 10 · MeSH hits: 1
Who's working on it?
62
Distinct author names in 11 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Ołdak M2 papers · 2015
Department of Genetics, Institute of Physiology and Pathology of Hearing, Mokra 17, Kajetany, 05-830, Nadarzyn, Poland, m.oldak@ifps.org.pl.
Papers in Europe PMC - 02Płoski R2 papers · 2015Papers in Europe PMC
- 03Pollak A2 papers · 2015Papers in Europe PMC
- 04Prekeris R2 papers · 2023
Department of Cell and Developmental Biology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. rytis.prekeris@cuanschutz.edu.
Papers in Europe PMC - 05Ruszkowska E2 papers · 2015Papers in Europe PMC
- 06Antonellis A1 paper · 2012Papers in Europe PMC
- 07Bai Y1 paper · 2012Papers in Europe PMC
- 08Banworth MJ1 paper · 2018
a Department of Biochemistry and Molecular Biology , University of Oklahoma Health Sciences Center , Oklahoma City , OK , USA.
Papers in Europe PMC - 09Bedoyan JK1 paper · 2012
Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA. donnamm@umich.edu
Papers in Europe PMC - 10Bianco AM1 paper · 2015
Department of Advanced Diagnostic and Clinical Trials, Institute for Maternal and Child Health ‑ IRCCS 'Burlo Garofolo', Trieste, Trieste 34137, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Deafness-intellectual disability syndrome, Martin-Probst type" OR "Hearing loss-intellectual disability syndrome, Martin-Probst type" OR "Martin-Probst syndrome" OR "X-linked deafness-intellectual disability syndrome" OR "X-linked hearing loss-intellectual disability syndrome" OR "X-linked deafness-intellectual disability syndrome syndrome" OR "intellectual disability, X-linked, syndromic, Martin-Probst type" OR "martin-probst syndrome, X-linked recessive" OR "mental retardation, X-linked, syndromic, Martin-Probst type"
MeSH descriptor terms unioned into the query: Martin-Probst Deafness-Mental Retardation Syndrome
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Deafness-intellectual disability syndrome, Martin-Probst type" OR "Hearing loss-intellectual disability syndrome, Martin-Probst type" OR "Martin-Probst syndrome" OR "X-linked deafness-intellectual disability syndrome" OR "X-linked hearing loss-intellectual disability syndrome" OR "X-linked deafness-intellectual disability syndrome syndrome" OR "intellectual disability, X-linked, syndromic, Martin-Probst type" OR "martin-probst syndrome, X-linked recessive" OR "mental retardation, X-linked, syndromic, Martin-Probst type" OR "Martin-Probst Deafness-Mental Retardation Syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:54:39.213Z